This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis was based on intention to treat. The primary outcome in the effectiveness analysis was mortality (survival time).
Effectiveness results
Actual survival time (observed time the patient was enrolled in the study) was an average of 4.3 months (95% CI: 3.9 -4.7) for epoprostenol/usual care and 4.7 months (95% CI: 4.2 -5.2) for usual care alone. This difference was not significant. Potential survival time (amount of time between the date of randomisation and the date at which the study was halted) was 6.2 months for epoprostenol/usual care and 6.3 months for usual care alone.
Clinical conclusions
Use of epoprostenol is associated with an increase in mortality.
Modelling
Modelling was performed to project (beyond the trial period) the costs and outcomes that would have been observed had all patients been randomised and followed for 12 months.
Measure of benefits used in the economic analysis
The benefit measure was quality-adjusted life months (QALMs). Quality of life expectancy was estimated based on responses to the EuroQol instrument. The product of the patient's survival time and their EuroQol scores generated quality-adjusted life months. Multiple regression analyses were used to allow for the assessment of differences in outcomes attributable to epoprostenol/usual care or usual care alone by controlling for other patient characteristics and also to project survival time (and costs) that would have been observed had all patients been followed for 12 months. A non-parametric bootstrap technique was used to estimate the 95% confidence intervals (CI) around the QALMs (and expected costs) and differences were assumed to be statistically significant if the 95% CI around the differences in QALMs (and mean costs) excluded zero.
Direct costs
Quantities and costs were analysed separately. Only health service costs were considered: inpatient hospital days, inpatient procedures, inpatient/outpatient physician visits, inpatient/outpatient nursing visits, outpatient laboratory evaluations, and non-acute care resources (e.g., nursing home, hospice or spa). Costs for inpatient services were derived from a cost accounting system in a single university hospital in the United States and costs for physician services were derived from the 1994 Medicare Fee Schedule. The use of epoprostenol and the resources required for the epoprostenol infusion system were recorded, but were not assigned costs and were omitted from the analysis because there was no market price for epoprostenol therapy at the time of writing. Costs of concomitant medications were also excluded.
Statistical analysis of costs
95% confidence intervals (CI) were generated around the projection of expected costs and QALMs had all patients been followed for 12 months using the nonparametric bootstrap procedure. Due to the potentially skewed nature of costs, an additional analysis to test for differences was performed on the log of total costs.
